Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 3 2Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1NET 1Gynecologic 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 230Squamous Cell Carcinoma of Head and Neck 139Head and Neck Neoplasms 131Lung Neoplasms 117Esophageal Neoplasms 88Stomach Neoplasms 84Uterine Cervical Neoplasms 68Esophageal Squamous Cell Carcinoma 66Urinary Bladder Neoplasms 59Breast Neoplasms 55Nasopharyngeal Carcinoma 51Small Cell Lung Carcinoma 46Carcinoma, Squamous Cell 39Neoplasm Metastasis 38Pancreatic Neoplasms 36Neoplasms 35Biliary Tract Neoplasms 34Oropharyngeal Neoplasms 32Cholangiocarcinoma 32Ovarian Neoplasms 30Mesothelioma, Malignant 28Adenocarcinoma Of Esophagus 28Lymphoma 25Carcinoma 24Adenocarcinoma of Lung 24Central Nervous System Neoplasms 22Laryngeal Neoplasms 20Carcinoma, Ovarian Epithelial 20Recurrence 19Lymphoma, Large B-Cell, Diffuse 19

Interventions

Pemetrexed 3Gemcitabine 3Topotecan 2Carboplatin 2vosaroxin 1vinflunine 1taxane 1pembrolizumab 1lurtotecan 1liposomal doxorubicin 1enzalutamide 1bemiparin 1apalutamide 1abiraterone 1Vinorelbine 1Temozolomide 1RRx-001 1Paclitaxel 1Nivolumab 1Irinotecan 1Ipilimumab 1Etoposide 1Docetaxel 1Cisplatin 1BI 2536 1Arsenic Trioxide 1ARQ 197 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Small Cell × Cisplatin × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡